Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 11 (November)

1. The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner.
   Int J Cancer, 122(1): 230-43. [Abstract] [Full-text]
2. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
   Int J Cancer, 122(1): 108-16. [Abstract] [Full-text]
3. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists.
   Int J Cancer, 122(1): 177-82. [Abstract] [Full-text]
4. Role of high-molecular weight tropomyosins in TGF-beta-mediated control of cell motility.
   Int J Cancer, 122(1): 78-90. [Abstract] [Full-text]
5. Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004.
   Int J Cancer, 122(1): 165-9. [Abstract] [Full-text]
6. Cleavage of BNIP-2 and BNIP-XL by caspases.
   Biochem Biophys Res Commun, 364(3): 495-501. [Abstract] [Full-text]
7. Hyperhomocysteinemia in women with advanced breast cancer.
   Int J Lab Hematol, 29(6): 421-5. [Abstract] [Full-text]
8. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells.
   Biochem J, 408(2): 203-10. [Abstract] [Full-text]
9. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
   Am J Hum Genet, 81(6): 1186-200. [Abstract] [Full-text]
10. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.
    Cancer Res, 67(22): 11001-11. [Abstract] [Full-text]
11. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Cancer Res, 67(22): 10910-9. [Abstract] [Full-text]
12. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
    Cancer Res, 67(22): 10804-12. [Abstract] [Full-text]
13. Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.
    Cancer Res, 67(22): 10774-81. [Abstract] [Full-text]
14. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells.
    Cancer Res, 67(22): 10694-702. [Abstract] [Full-text]
15. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.
    Cancer Res, 67(22): 10669-76. [Abstract] [Full-text]
16. Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer.
    Am J Surg, 194(6): 860-4; discussion 864-5. [Abstract] [Full-text]
17. Solitary positive sentinel lymph node accompanied by negative sentinel lymph node(s) is predictive of a negative completion axillary lymph node dissection.
    Am J Surg, 194(6): 856-8; discussion 858-9. [Abstract] [Full-text]
18. The optimal management of the axillae of patients with microinvasive breast cancer in the sentinel lymph node era.
    Am J Surg, 194(6): 845-8; discussion 848-9. [Abstract] [Full-text]
19. The genomic landscapes of human breast and colorectal cancers.
    Science, 318(5853): 1108-13. [Abstract] [Full-text]
20. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
    J Clin Oncol, 25(33): 5187-93. [Abstract] [Full-text]
21. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    J Clin Oncol, 25(33): 5210-7. [Abstract] [Full-text]
22. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    J Clin Oncol, 25(33): 5194-202. [Abstract] [Full-text]
23. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.
    J Clin Oncol, 25(33): 5203-9. [Abstract] [Full-text]
24. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    J Clin Oncol, 25(33): 5287-312. [Abstract] [Full-text]
25. An oncoplastic procedure for central and medio-cranial breast cancer.
    Eur J Surg Oncol, 33(10): 1158-63. [Abstract] [Full-text]
26. Radioguided Intraoperative Margins Evaluation (RIME): preliminary results of a new technique to aid breast cancer resection.
    Eur J Surg Oncol, 33(10): 1150-7. [Abstract] [Full-text]
27. Local recurrence of stage 1 and 2 breast cancer after skin-sparing mastectomy and immediate breast reconstruction in a 15-year series.
    Eur J Surg Oncol, 33(10): 1142-5. [Abstract] [Full-text]
28. Sentinel node biopsy with intraoperative diagnosis in patients undergoing skin-sparing mastectomy and immediate breast reconstruction.
    Eur J Surg Oncol, 33(10): 1146-9. [Abstract] [Full-text]
29. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade.
    Radiology, 245(3): 684-91. [Abstract] [Full-text]
30. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
    Am J Clin Pathol, 128(6): 1041-9. [Abstract] [Full-text]
31. Monomorphic epithelial proliferations: characterization and evidence suggesting they are the pool of partially transformed lesions from which some invasive carcinomas arise.
    Am J Clin Pathol, 128(6): 1023-34. [Abstract] [Full-text]
32. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.
    Radiology, 245(3): 824-30. [Abstract] [Full-text]
33. Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction.
    Radiology, 245(3): 742-50. [Abstract] [Full-text]
34. Breast lymphoma: imaging findings of 32 tumors in 27 patients.
    Radiology, 245(3): 692-702. [Abstract] [Full-text]
35. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
    Cancer Immunol Immunother, 57(2): 271-80. [Abstract] [Full-text]
36. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    J Natl Cancer Inst, 99(22): 1683-94. [Abstract] [Full-text]
37. Challenges in projecting clustering results across gene expression-profiling datasets.
    J Natl Cancer Inst, 99(22): 1715-23. [Abstract] [Full-text]
38. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    J Natl Cancer Inst, 99(22): 1695-705. [Abstract] [Full-text]
39. Dedicated cone-beam breast CT: feasibility study with surgical mastectomy specimens.
    AJR Am J Roentgenol, 189(6): 1312-5. [Abstract] [Full-text]
40. Imaging differences in metaplastic and invasive ductal carcinomas of the breast.
    AJR Am J Roentgenol, 189(6): 1288-93. [Abstract] [Full-text]
41. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures.
    Nat Clin Pract Oncol, 4(12): 699-710. [Abstract] [Full-text]
42. Inhibition of cellular proliferation by the genistein metabolite 5,7,3',4'-tetrahydroxyisoflavone is mediated by DNA damage and activation of the ATR signalling pathway.
    Arch Biochem Biophys, 468(2): 159-66. [Abstract] [Full-text]
43. An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer.
    Mol Cell Biol, 27(24): 8648-57. [Abstract] [Full-text]
44. Haplotypes of the estrogen receptor beta gene and breast cancer risk.
    Int J Cancer, 122(2): 387-92. [Abstract] [Full-text]
45. Diagnostic performance of stereotactic large core needle biopsy for nonpalpable breast lesions in routine clinical practice.
    Int J Cancer, 122(2): 468-71. [Abstract] [Full-text]
46. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
    Int J Cancer, 122(2): 461-7. [Abstract] [Full-text]
47. Socio-demographic determinants of participation in mammography screening.
    Int J Cancer, 122(2): 418-23. [Abstract] [Full-text]
48. Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status--a prospective cohort study among Swedish women.
    Int J Cancer, 122(2): 403-12. [Abstract] [Full-text]
49. Thoracic paravertebral block for breast cancer surgery: a randomized double-blind study.
    Anesth Analg, 105(6): 1848-51, table of contents. [Abstract] [Full-text]
50. The histological diagnosis of metastases to the breast from extramammary malignancies.
    J Clin Pathol, 60(12): 1333-41. [Abstract] [Full-text]
51. Non-operative breast pathology: apocrine lesions.
    J Clin Pathol, 60(12): 1313-20. [Abstract] [Full-text]
52. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.
    J Clin Pathol, 60(12): 1300-6. [Abstract] [Full-text]
53. Demystifying basal-like breast carcinomas.
    J Clin Pathol, 60(12): 1328-32. [Abstract] [Full-text]
54. Non-operative breast pathology: lobular neoplasia.
    J Clin Pathol, 60(12): 1321-7. [Abstract] [Full-text]
55. Non-operative breast pathology: columnar cell lesions.
    J Clin Pathol, 60(12): 1307-12. [Abstract] [Full-text]
56. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
    Anticancer Drugs, 19(1): 1-7. [Abstract] [Full-text]
57. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
    J Clin Oncol, 25(34): 5418-25. [Abstract] [Full-text]
58. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    J Clin Oncol, 25(34): 5410-7. [Abstract] [Full-text]
59. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    J Clin Oncol, 25(34): 5403-9. [Abstract] [Full-text]
60. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.
    FASEB J, 21(14): 4013-27. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.